PST

Momcozy and Arianna Criscione, Professional Soccer Player & Women's Sports Advocate, Unite for International Women's Day Campaign

Retrieved on: 
Thursday, March 7, 2024

Arianna Criscione is celebrated not only for her remarkable career as a professional soccer goalkeeper but also for her impactful contributions off the field.

Key Points: 
  • Arianna Criscione is celebrated not only for her remarkable career as a professional soccer goalkeeper but also for her impactful contributions off the field.
  • She is a founding member of Mercury/13 , a multi-club ownership group, proving women's soccer has an economic upside.
  • Ultimately, Momcozy and Arianna Criscione's collaboration is more than a campaign; it's a movement toward recognizing and celebrating the diverse experiences of motherhood.
  • As International Women's Day approaches, join Momcozy and Arianna in this heartfelt celebration of motherhood.

Modelo Partners with MotorTrend to Publish Limited-Edition Revival of Lowrider Magazine Dedicated to the Women Shaping the Culture

Retrieved on: 
Thursday, March 7, 2024

To spotlight those who haven’t always received recognition, Modelo has teamed up with MotorTrend to launch a special edition of Lowrider magazine that champions the women of lowriding throughout the entire issue.

Key Points: 
  • To spotlight those who haven’t always received recognition, Modelo has teamed up with MotorTrend to launch a special edition of Lowrider magazine that champions the women of lowriding throughout the entire issue.
  • “Modelo has always stood for those with grit and tenacity who demonstrate the mark of a fighter – traits the lowrider community certainly embodies,” said Logan Jensen, Sr. Director of Brand Marketing, Modelo.
  • Modelo donated advertising space in the publication to women-owned businesses to further support and spotlight the entrepreneurs impacting the lowrider industry.
  • Beyond the canvas, this artist and lowrider owner started the Prophets Car Club, which encourages both women and LGBTQ+ membership.

Crescendo Biologics to present at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, will be presenting two poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.

Key Points: 
  • Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, will be presenting two poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
  • Archer, S et al, CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumors, Poster Section 3, Abstract #5313
    Pierce, AJ et al, CB699: A novel mesothelin-binding Humabody® CD40 and CD137 dual-agonist for enhancing immune cell responses against MSLN+ tumors, Poster Section 3, Abstract #5302
    Both posters will be presented in the Immune Modulation Employing Agonist or Co-Stimulatory Approaches Session, on Tuesday 9 April 2024, 1:30 pm - 5:00 pm PST, and will be made available on the Publications section of the company’s website following their presentation at the meeting.

HashiCorp Announces Fourth Quarter and Fiscal Year 2024 Financial Results

Retrieved on: 
Tuesday, March 5, 2024

Fourth quarter revenue totaled $155.8 million, representing an increase of 15% year-over-year; fiscal 2024 revenue totaled $583.1 million, representing an increase of 23% year-over-year

Key Points: 
  • Fourth quarter revenue totaled $155.8 million, representing an increase of 15% year-over-year; fiscal 2024 revenue totaled $583.1 million, representing an increase of 23% year-over-year
    Trailing four quarter average Net Dollar Retention Rate was 115% at the end of the fourth quarter of fiscal 2024 and 131% at the end of fourth quarter of fiscal 2023.
  • SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today announced financial results for its fourth quarter and full fiscal year 2024, ended January 31, 2024.
  • HashiCorp ended the fourth quarter of fiscal 2024 with 4,423 customers, up from 4,354 customers at the end of the previous fiscal quarter and 3,870 customers at the end of the fourth quarter of fiscal 2023.
  • Quarterly subscription revenue from HashiCorp Cloud Platform (HCP) reached $21.3 million in the fourth quarter of fiscal 2024, increased from $19.9 million in the previous fiscal quarter and increased from $14.5 million in the fourth quarter of fiscal 2023.

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Retrieved on: 
Monday, March 4, 2024

Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.

Key Points: 
  • Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.
  • The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B.
  • Key members of the MoonLake team, including the executive leadership team, will attend AAD.
  • This was followed by an announcement in October 2023, reporting from the trial at 24 weeks, further establishing sonelokimab as a highly promising and differentiated therapeutic solution for HS.

Evercommerce To Present at the Citizens JMP Technology Conference

Retrieved on: 
Thursday, February 29, 2024

DENVER, Feb. 29, 2024 (GLOBE NEWSWIRE) -- EverCommerce Inc. (NASDAQ: EVCM), a leading service commerce platform, today announced that management will present at the following upcoming investor conference:

Key Points: 
  • DENVER, Feb. 29, 2024 (GLOBE NEWSWIRE) -- EverCommerce Inc. (NASDAQ: EVCM), a leading service commerce platform, today announced that management will present at the following upcoming investor conference:
    Senior Vice President and Head of Investor Relations Brad Korch, will present at the Citizens JMP Technology Conference in San Francisco.
  • The presentation is scheduled for Monday, March 4, 2024 at 8:30 a.m. PST.
  • The links to the live webcasts for the conference will be made available through the Investor Relations section of the Company’s website at: https://investors.evercommerce.com .

Vivid Seats to Participate in Morgan Stanley’s 2024 Technology, Media & Telecom Conference

Retrieved on: 
Thursday, February 29, 2024

CHICAGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced that Stan Chia, Chief Executive Officer, and Lawrence Fey, Chief Financial Officer, will be presenting at Morgan Stanley’s 2024 Technology, Media & Telecom Conference on Wednesday, March 6, 2024 at 1:20 p.m. PST.

Key Points: 
  • CHICAGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced that Stan Chia, Chief Executive Officer, and Lawrence Fey, Chief Financial Officer, will be presenting at Morgan Stanley’s 2024 Technology, Media & Telecom Conference on Wednesday, March 6, 2024 at 1:20 p.m. PST.

SiTime to Present at the Morgan Stanley Technology, Media & Telecom Conference on March 5

Retrieved on: 
Tuesday, February 27, 2024

SANTA CLARA, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- SiTime Corporation (Nasdaq: SITM), the precision timing company, today announced that SiTime’s CEO, Rajesh Vashist, and CFO, Beth Howe, will present at the Morgan Stanley Technology, Media & Telecom Conference to be held at the Palace Hotel in San Francisco, CA.

Key Points: 
  • SANTA CLARA, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- SiTime Corporation (Nasdaq: SITM), the precision timing company, today announced that SiTime’s CEO, Rajesh Vashist, and CFO, Beth Howe, will present at the Morgan Stanley Technology, Media & Telecom Conference to be held at the Palace Hotel in San Francisco, CA.
  • SiTime management is scheduled to host a fireside chat at 3:35 p.m. PST on Tuesday, March 5, 2024.
  • A live and archived webcast of the Company’s fireside chat will be available in the Events section of SiTime’s Investor Relations website.

AVITA Medical to Host Investor Webinar Briefing

Retrieved on: 
Friday, February 23, 2024

VALENCIA, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 27, 2024, at 2:00 p.m. (PST) / February 28, 2024, at 9:00 a.m. (AEDT).

Key Points: 
  • VALENCIA, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 27, 2024, at 2:00 p.m. (PST) / February 28, 2024, at 9:00 a.m. (AEDT).
  • The webinar presentation will cover financial highlights from our recent fourth quarter and full-year 2023 earnings webcast, business highlights, 2024 revenue guidance, and conclude with a Q&A session.
  • To register for the presentation, please follow this Zoom link:

Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid

Retrieved on: 
Tuesday, February 20, 2024

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.
  • The study consented 12 patients who were assessed for eligibility to receive the investigational drug treatment.
  • Preliminary data indicate an 84% average reduction in ulcer surface area for the 9 patients completing the 12-week study.
  • These data are being analyzed by the Merakris scientific team and an independent data safety and monitoring committee and will inform the design of Part 2 of the multi-center clinical study.